SS 31 Why 40mg Is the Wrong Dose And What Actually Works

The number 40 milligrams has spread through online discussions of SS-31 the way a lot of numbers spread, which is by being repeated without context until the context disappears entirely.

Here is where it actually came from.

A clinical trial called TAZPOWER was designed to evaluate something called elamipretide, which is the pharmaceutical name for SS-31, in patients with Barth syndrome. Barth syndrome is a rare genetic disorder affecting roughly 150 people in the United States, caused by a mutation in a gene called TAZ that prevents mitochondria from producing functional cardiolipin. That 40 milligram daily dose was built for that population, and understanding what cardiolipin actually is explains why the dose for that condition has almost nothing to do with age-related mitochondrial decline.

Cardiolipin is a phospholipid, which is a type of fat-based molecule, that sits in the inner membrane of your mitochondria and acts as the structural anchor for the proteins that generate energy. Think of the inner mitochondrial membrane as an assembly line and cardiolipin as the scaffolding that holds every machine on that line in the correct position. When cardiolipin is functional, the proteins that shuttle electrons through what is called the electron transport chain stay properly organized, electrons move efficiently, and your mitochondria produce ATP the way they are supposed to. When cardiolipin is damaged or absent, those protein complexes drift apart, electron transfer becomes inefficient, and a significant portion of the energy that should become ATP leaks out as free radicals instead.

SS-31 works by selectively binding to cardiolipin, stabilizing it within the membrane, and in doing so it reduces what is called electron leakage, which is the proportion of electrons that escape the transport chain and generate oxidative damage rather than usable energy. Research from Hazel Szeto's lab has shown that this reduction in leakage is not trivial, running somewhere in the range of 40 to 60 percent depending on the model being studied.

Now here is what makes the TAZPOWER dose irrelevant to most people reading this.

In Barth syndrome, the mitochondria have never worked correctly. These patients are born without the genetic machinery to produce functional cardiolipin at all. Their entire energy production system has been structurally compromised from day one. The 40 milligram dose used in TAZPOWER was calibrated for that level of mitochondrial failure, the kind where the scaffolding was never built in the first place.

Age-related mitochondrial decline is a completely different situation. If you are 40 or 50 years old and dealing with slower recovery, declining energy, or reduced aerobic capacity, your mitochondria started out functioning normally. What has happened over decades is accumulation: oxidative stress, inflammation, and the normal wear of metabolic activity have progressively damaged the cardiolipin that was originally intact. The scaffolding exists, it has just been degraded over time. That is not a rebuild from nothing. That is structural repair.

Using the dose designed for the first scenario to address the second is the equivalent of using a complete engine replacement protocol on a car that needs its gaskets cleaned.

Preclinical work in aged mice has supported this distinction. Research by Sweetwyne and colleagues showed that SS-31 improved glomerular architecture, meaning the structural integrity of kidney filtration units, in mice of advanced age at doses that translate, when adjusted for human body surface area, to a fraction of what was used in TAZPOWER. The aging mice were not missing cardiolipin entirely. They had cardiolipin that had been damaged over time, and the lower doses were sufficient to stabilize what remained.

For age-related mitochondrial decline in otherwise healthy adults, the practical evidence, which at this dose range means preclinical research and clinical observation rather than large randomized trials, supports 1 to 2 milligrams daily over a period of 4 to 8 weeks. That number is not derived from a phase 2/3 trial at that specific dose, and that distinction matters and should be stated plainly.

What is also worth stating plainly is the financial math, because it makes the dosing question concrete in a way that abstract percentages do not.

At 40 milligrams per day, SS-31 costs approximately 200 dollars per day. At 2 milligrams per day, that cost drops to approximately 10 dollars per day. That is a 20-fold difference in cost for a dose that was never calibrated for the biology you are actually trying to address. For someone without a genetic defect in cardiolipin synthesis, the higher dose does not produce additional benefit proportional to the additional cost. It produces a number that came from a different question entirely.

The deeper point here is about how clinical trial data travels outside the context that generated it. TAZPOWER was a well-designed trial answering a specific question about a specific population, and 40 milligrams was the right answer to that question. The problem is not the research. The problem is that a number extracted from a rare disease trial became the default recommendation for a completely different use case, because the number was visible and the context was not.

When you see a dose number from a clinical trial, the question worth asking is not whether the trial was credible. It is whether you share the biology the trial was designed around. In this case, the answer for almost everyone asking about SS-31 for energy and recovery is no, and that changes everything about what the number means.

---

References

1. Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genetics in Medicine. 2021;23:471-478. Source of the 40mg daily dose used in the TAZPOWER trial for Barth syndrome. Source
2. Sweetwyne MT, et al. The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney International. 2017;91:1126-1145. Preclinical dose translation basis for optimization dosing. Source
3. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171:2029-2050. Mechanism of action: SS-31 binds cardiolipin, stabilizes mitochondrial membrane structure, reduces electron leakage by 40-60%. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness